276 related articles for article (PubMed ID: 36517926)
21. Survey of barriers and opportunities for prescribing buprenorphine for opioid use disorder in Alabama.
Patel I; Li L; Jeong H; McDaniel JT; McIntosh S; Robertson E; Albright DL
J Addict Dis; 2023 Aug; ():1-8. PubMed ID: 37650610
[TBL] [Abstract][Full Text] [Related]
22. Differences in perceived clinical knowledge uptake among health profession students and licensed clinicians receiving buprenorphine waiver training in Oregon.
Robbins JL; Bonuck K; Thuillier P; Buist C; Carney PA
Subst Abus; 2022; 43(1):825-833. PubMed ID: 35130133
[No Abstract] [Full Text] [Related]
23. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
[TBL] [Abstract][Full Text] [Related]
24. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
25. Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses.
Andraka-Christou B; Totaram R; Randall-Kosich O
Subst Abus; 2022; 43(1):415-424. PubMed ID: 34214400
[No Abstract] [Full Text] [Related]
26. A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.
Taylor EN; Timko C; Binswanger IA; Harris AHS; Stimmel M; Smelson D; Finlay AK
Subst Abus; 2022; 43(1):556-563. PubMed ID: 34586978
[No Abstract] [Full Text] [Related]
27. Buprenorphine Waiver Attitudes Among Primary Care Providers.
Lai B; Croghan I; Ebbert JO
J Prim Care Community Health; 2022; 13():21501319221112272. PubMed ID: 35822763
[TBL] [Abstract][Full Text] [Related]
28. Attitudes and beliefs among Georgia addiction treatment staff about medication for opioid use disorder in adolescents, young adults, and adults: a multi-mixed methods study.
Welsh JW; Mataczynski MJ; Passetti LL; Hunter BD; Godley MD
Am J Drug Alcohol Abuse; 2022 May; 48(3):347-355. PubMed ID: 35416739
[No Abstract] [Full Text] [Related]
29. Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings.
Gordon AJ; Kenny M; Dungan M; Gustavson AM; Kelley AT; Jones AL; Hawkins E; Frank JW; Danner A; Liberto J; Hagedorn H
Am J Addict; 2022 Mar; 31(2):152-158. PubMed ID: 35118756
[TBL] [Abstract][Full Text] [Related]
30. Perspectives on APRN prescribing of medications for opioid use disorder: Key barriers remain.
Chapman SA; Fraimow-Wong L; Phoenix BJ; Tierney M; Spetz J
J Subst Use Addict Treat; 2024 Feb; 157():209215. PubMed ID: 37979946
[TBL] [Abstract][Full Text] [Related]
31. Integrating DATA 2000 waiver training into undergraduate medical education: The time is now.
Riser E; Holterman LA; Maruti S; Brooklyn JR; DeVoe SG; Tompkins BJ; Drouin J; Sobel HG
Subst Abus; 2021; 42(2):236-243. PubMed ID: 33821773
[No Abstract] [Full Text] [Related]
32. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
[TBL] [Abstract][Full Text] [Related]
33. System-level factors shaping the implementation of "hub and spoke" systems to expand MOUD in rural areas.
Snell-Rood C; Willging C; Showalter D; Peters H; Pollini RA
Subst Abus; 2021; 42(4):716-725. PubMed ID: 33284083
[No Abstract] [Full Text] [Related]
34. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder.
Andrilla CHA; Patterson DG
J Rural Health; 2022 Jan; 38(1):87-92. PubMed ID: 33733547
[TBL] [Abstract][Full Text] [Related]
35. Effects of Bundling Medication for Opioid Use Disorder With an mHealth Intervention Targeting Addiction: A Randomized Clinical Trial.
Gustafson DH; Landucci G; Vjorn OJ; Gicquelais RE; Goldberg SB; Johnston DC; Curtin JJ; Bailey GL; Shah DV; Pe-Romashko K; Gustafson DH
Am J Psychiatry; 2024 Feb; 181(2):115-124. PubMed ID: 37789744
[TBL] [Abstract][Full Text] [Related]
36. Providing Incentive for Emergency Physician X-Waiver Training: An Evaluation of Program Success and Postintervention Buprenorphine Prescribing.
Foster SD; Lee K; Edwards C; Pelullo AP; Khatri UG; Lowenstein M; Perrone J
Ann Emerg Med; 2020 Aug; 76(2):206-214. PubMed ID: 32376089
[TBL] [Abstract][Full Text] [Related]
37. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
Jones CM; McCance-Katz EF
Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
[TBL] [Abstract][Full Text] [Related]
38. Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities.
Walters SM; Perlman DC; Guarino H; Mateu-Gelabert P; Frank D
Subst Use Misuse; 2022; 57(7):1144-1153. PubMed ID: 35443862
[No Abstract] [Full Text] [Related]
39. Prescribing Practices of Nurse Practitioners and Physician Assistants Waivered to Prescribe Buprenorphine and the Barriers They Experience Prescribing Buprenorphine.
Andrilla CHA; Jones KC; Patterson DG
J Rural Health; 2020 Mar; 36(2):187-195. PubMed ID: 31650634
[TBL] [Abstract][Full Text] [Related]
40. Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.
Andrilla CHA; Moore TE; Patterson DG; Larson EH
J Rural Health; 2019 Jan; 35(1):108-112. PubMed ID: 29923637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
